Certain intrinsic features of lung cancer tumors have served as biomarkers that can predict response to immunotherapy, including tumor mutational burden and PD-L1 expression in malignant cells, both of which are currently approved by the United States Food and Drug Administration (FDA) as standard biomarkers for ICI treatment in patients with NSCLC [12,38]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.